Alphatec (ATEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for June 10, 2026, with voting on key proposals including director elections, auditor ratification, equity and stock purchase plans, and executive compensation approval.
Shareholders of record as of April 15, 2026, are entitled to vote, with 153,702,057 shares outstanding.
Proxy materials are primarily delivered electronically to conserve resources and reduce costs.
Voting matters and shareholder proposals
Proposals include electing seven directors, ratifying Deloitte & Touche LLP as auditor, approving the 2026 Equity Incentive Plan, approving the 2026 Employee Stock Purchase Plan, and an advisory vote on executive compensation.
The board recommends voting FOR all proposals.
Voting can be done online, by phone, mail, or in person; each share has one vote, and cumulative voting is not permitted.
Broker non-votes will not affect the outcome for non-routine matters.
Board of directors and corporate governance
The board consists of seven directors, with a mix of independent and non-independent members.
Leadership structure allows flexibility between combined or separate CEO and Chairman roles; currently, the CEO also serves as Chairman.
Committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.
The board encourages diversity and considers a broad range of perspectives in director nominations.
Latest events from Alphatec
- Q1 2026 revenue up 14% to $192M, with EBITDA doubling and debt costs set to drop $6M+.ATEC
Q1 202611 May 2026 - Shareholders to vote on board elections, auditor ratification, and key compensation plans.ATEC
Proxy filing29 Apr 2026 - 2025 revenue up 25% to $764M; 2026 guidance raised to $890M and $134M adjusted EBITDA.ATEC
Q4 20259 Apr 2026 - Surgeon adoption, enabling tech, and disciplined capital deployment drive robust growth and share gains.ATEC
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Q3 2024 revenue up 27%, adjusted EBITDA positive, and liquidity boosted by $50M term loan.ATEC
Q3 202413 Feb 2026 - Q2 revenue up 25% to $146M, margin expansion, positive EBITDA, and guidance raised.ATEC
Q2 202413 Feb 2026 - Rapid growth driven by procedural innovation, margin leverage, and targeted expansion.ATEC
Jefferies Global Healthcare Conference1 Feb 2026 - Spine-focused innovation and informatics drive strong growth, profitability, and global expansion.ATEC
44th Annual J.P. Morgan Healthcare Conference30 Jan 2026 - Inventory investment to decline, supporting free cash flow break even in 2025 and robust growth.ATEC
2024 Wells Fargo Healthcare Conference22 Jan 2026